AUG 17 2026
Deciphera Pharmaceuticals — tirabrutinib
for relapsed or refractory primary central nervous system lymphoma
About
Primary central nervous system lymphoma (PCNSL) is an aggressive brain tumor that often strikes people with weakened immune systems, growing rapidly in the nervous system. Tirabrutinib blocks a protein called Bruton’s tyrosine kinase (BTK) that helps cancerous B-cells multiply and survive. By interrupting this growth signal, the drug may slow the lymphoma’s spread while being easier to tolerate than current combination therapies.
Pivotal trial
The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL).
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on tirabrutinib
- Ono’s Real-World Tirabrutinib Study in Taiwan Reaches Completion, Setting Up a New Catalyst for OPHLF - TipRanks
- Deciphera Pharmaceuticals Secures FDA NDA Acceptance For Tirabrutinib In R R PCNSL - BioPharma APAC
- Tirabrutinib NDA Cleared by the FDA in Relapsed/Refractory PCNSL - CancerNetwork
- FDA Accepts NDA for Tirabrutinib in Relapsed/Refractory PCNSL - OncLive
- FDA Accepts Tirabrutinib Application for Relapsed PCNSL - Cure Today